文献速递眼底病与葡萄膜炎

半剂量光动力疗法对比依普利酮治疗慢性中心性浆液性脉络膜视网膜病变(SPECTRA):随机对照试验

Half-Dose Photodynamic Therapy Versus Eplerenone in Chronic Central Serous Chorioretinopathy (SPECTRA): A Randomized Controlled Trial.
PubMed 文献 · Am J Ophthalmol · 2021-06-29

SPECTRA 多中心开放标签随机对照试验在荷兰 3 家学术医学中心纳入 107 例慢性中心性浆液性脉络膜视网膜病变患者,1:1 随机接受吲哚菁绿血管造影引导的半剂量光动力疗法或口服依普利酮 12 周。3 个月时半剂量光动力疗法组视网膜下液完全吸收率 78%,显著高于依普利酮组的 17%(P < .001),且不良事件更少(6% vs 33%)。两组最佳矫正视力无显著差异,但光动力疗法组微视野视网膜敏感度更优。

要点

  • 半剂量光动力疗法 3 个月视网膜下液完全吸收率 78%,显著优于依普利酮的 17%。
  • 两组最佳矫正视力无显著差异(83.7 vs 82.8 ETDRS 字母,P = .555)。
  • 光动力疗法组不良事件发生率 6%,低于依普利酮组的 33%。

核心结论

  • 半剂量光动力疗法在慢性中心性浆液性脉络膜视网膜病变的短期安全性和疗效方面均优于口服依普利酮。

研究设计与样本

  • 多中心、开放标签、随机对照试验,在荷兰 3 家学术医学中心开展。
  • 共 107 例患者按 1:1 随机分配至吲哚菁绿血管造影引导的半剂量光动力疗法组(n = 53)或口服依普利酮 12 周组(n = 54)。
  • 在治疗开始后 3 个月评估解剖和功能结局。

主要发现

  • 3 个月时光动力疗法组 78% 患者视网膜下液完全吸收,依普利酮组仅 17%(P < .001)。
  • 3 个月时最佳矫正视力(ETDRS 字母)光动力疗法组为 83.7 ± 10.8,依普利酮组为 82.8 ± 9.0(P = .555)。
  • 微视野平均视网膜敏感度光动力疗法组为 25.4 ± 3.4 dB,依普利酮组为 23.9 ± 4.0 dB(P = .041)。
  • 平均视功能相关生活质量评分光动力疗法组为 87.2 ± 8.5,依普利酮组为 83.8 ± 12.1(P = .094)。
  • 光动力疗法组 3 例(6%)发生不良事件,依普利酮组 18 例(33%)发生不良事件。

临床怎么用

  • 对于慢性中心性浆液性脉络膜视网膜病变,半剂量光动力疗法可作为优先考虑的短期治疗方案,其视网膜下液吸收率和安全性优于口服依普利酮。

局限性

  • 光动力疗法组 3 例、依普利酮组 10 例未遵守研究方案。
  • 研究为开放标签设计,随访评估时间为治疗开始后 3 个月。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare the efficacy and safety between half-dose photodynamic therapy (PDT) and eplerenone therapy for treating chronic central serous chorioretinopathy (cCSC). DESIGN: This was a multicenter, open-label, randomized controlled trial. METHODS: This investigator-initiated trial was conducted in 3 academic medical centers in the Netherlands. Eligible patients were randomized at a 1:1 ratio to receive either indocyanine green angiography-guided half-dose PDT or oral eplerenone for 12 weeks. Both anatomical and functional outcomes were evaluated at 3 months after the start of treatment. RESULTS: A total of 107 patients were randomly assigned to receive either half-dose PDT (n = 53) or eplerenone treatment (n = 54). Thirteen patients (3 in the PDT group and 10 in the eplerenone group) did not adhere to the study protocol. At the 3-month evaluation visit, 78% of patients in the PDT group had complete resolution of subretinal fluid accumulation compared to only 17% of patients in the eplerenone group (P < .001). Mean best-corrected visual acuity in Early Treatment of Diabetic Retinopathy Study letters at the 3-month evaluation visit was 83.7 ± 10.8 and 82.8 ± 9.0 in the PDT and eplerenone groups, respectively (P = .555). In addition, mean retinal sensitivity on microperimetry was 25.4 ± 3.4 dB and 23.9 ± 4.0 dB in the PDT and eplerenone groups, respectively (P = .041). Finally, mean vision-related quality of life scores were 87.2 ± 8.5 and 83.8 ± 12.1 in the PDT and eplerenone groups, respectively (P = .094). Three patients (6%) in the PDT group experienced adverse events during the study compared to 18 patients (33%) in the eplerenone group. CONCLUSIONS: Half-dose PDT is superior to oral eplerenone for cCSC with respect to both short-term safety and efficacy outcomes.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. van Rijssen TJ, van Dijk EHC, Tsonaka R, et al. Half-Dose Photodynamic Therapy Versus Eplerenone in Chronic Central Serous Chorioretinopathy (SPECTRA): A Randomized Controlled Trial. Am J Ophthalmol. 2021. PMID: 34214454. doi:10.1016/j.ajo.2021.06.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。